Norges Bank’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Norges Bank’s Portfolio LJPC Stock Details LJPC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-259,676	Closed	-$1.1M	–	2310
2021 Q1	$1.1M	Buy	+259,676	New	+$1.43M	﹤0.01%	2041

Other funds holding LJPC

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank's LJPC Position: Q2 2021 in Review

Norges Bank sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2021, closing a stake of 259,676 shares — an estimated $1.1M sold.

Norges Bank first reported a position in LJPC in Q1 2021 and held it in 1 quarter. The position peaked at $1.1M in Q1 2021. 62 funds tracked by Wall St. Rank hold LJPC as of Q2 2021.

Norges Bank reported no remaining La Jolla Pharmaceutical Company position as of Q2 2021 after selling out during the quarter.
Norges Bank sold 259,676 La Jolla Pharmaceutical Company shares in Q2 2021, an estimated $1.1M.
Norges Bank first reported a position in La Jolla Pharmaceutical Company in Q1 2021 and held it in 1 quarter.
Norges Bank's La Jolla Pharmaceutical Company position peaked at $1.1M in Q1 2021.
62 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2021.

Based on Norges Bank's 13F filing for Q2 2021, filed 10 Aug 2021.